MARKET

INCY

INCY

Incyte Corp
NASDAQ
120.97
-0.73
-0.60%
After Hours: 120.02 -0.95 -0.79% 19:30 11/13 EST
OPEN
121.89
PREV CLOSE
121.70
HIGH
122.07
LOW
119.72
VOLUME
950.51K
TURNOVER
--
52 WEEK HIGH
132.60
52 WEEK LOW
89.25
MARKET CAP
24.66B
P/E (TTM)
64.32
1D
5D
1M
3M
1Y
5Y
1D
Incyte won't move ahead with phase 3 trial of ovarian cancer asset
Seeking Alpha · 23h ago
Incyte Discontinues Planned Phase 3 Ovarian Cancer Study
TipRanks · 1d ago
Incyte Has Decided Not To Proceed With The Planned Phase 3 MAESTRA-3 Study Evaluating INCB123667; Company Does Not Expect This Determination To Affect Its Financial Guidance Or Its Previously Disclosed Long-term Outlook
Benzinga · 1d ago
Incyte will not proceed with planned Phase 3 MAESTRA-3 study of INCB123667
TipRanks · 1d ago
Incyte (INCY) Expands Beyond JAKAFI, Is The Stock Still Cheap?
Simply Wall St · 2d ago
Natera announces clinical collaboration with Incyte
TipRanks · 4d ago
Natera Enters Into Clinical Collaboration Agreement With Incyte For New Phase II Study In Colorectal Cancer
Benzinga · 4d ago
Analysts’ Top Healthcare Picks: Pacific Edge Limited (PFGTF), ADC Therapeutics (ADCT)
TipRanks · 4d ago
More
About INCY
Incyte Corporation is a biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutics. It operates in three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity. Its hematology franchise includes four approved products, JAKAFI (ruxolitinib), ICLUSIG (ponatinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) and NIKTIMVO (axatilimab-csfr), as well as multiple clinical development programs. Its oncology franchise includes two approved products, PEMAZYRE (pemigatinib) and ZYNYZ (retifanlimab-dlwr), as well as several clinical development programs. Its Inflammation and Autoimmunity franchise consists of one approved product, OPZELURA (ruxolitinib) cream, with several clinical programs in development. It also includes VGA039, a novel monoclonal antibody in Phase III development for von Willebrand disease (VWD). It manages business activities through the development and commercialization of oncology and dermatology products.

Webull offers Incyte Corp stock information, including NASDAQ: INCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INCY stock methods without spending real money on the virtual paper trading platform.